The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants.

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.